Armed with $42.5M, Gem­i­ni em­braces the Goldilocks strat­e­gy in bring­ing pre­ci­sion med to AMD

For most biotech star­tups, the big chal­lenge lies in de­vel­op­ing one or two new drugs that promise to do a bet­ter job of tar­get­ing a par­tic­u­lar dis­ease.

But Gem­i­ni Ther­a­peu­tics — the lat­est in a long line­up of Cam­bridge, MA biotechs to roll out this year — isn’t like most up­starts.

CEO James McLaugh­lin has set out to divvy up the large pop­u­la­tion of pa­tients at high risk of dry age-re­lat­ed mac­u­lar de­gen­er­a­tion — AMD — in­to small, ge­net­i­cal­ly de­fined buck­ets of pa­tients, and then find the right drug most like­ly to help them. And that’s big enough to even­tu­al­ly in­volve a whole pipeline of ther­a­peu­tics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER